China Pharma Holdings (CPHI) Change in Receivables (2010 - 2026)
China Pharma Holdings (CPHI) posted Change in Receivables of $14019.0 for Q1 2026, up 100.1% on a QoQ basis from -$13.5 million in Q4 2025, and down 91.49% year-over-year from $164670.0 in Q1 2025.
China Pharma Holdings (CPHI) Change in Receivables (2010 - 2026) Analysis & Trends
China Pharma Holdings' Change in Receivables history runs 17 years deep, the most recent figure standing at $14019.0 for Q1 2026.
- Quarterly Change in Receivables fell 91.49% year-over-year to $14019.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$13.4 million (down 2867.3% YoY) and the FY2025 annual result came in at -$13.2 million, down 6780.77% from the prior year.
- Change in Receivables was $14019.0 for Q1 2026 at China Pharma Holdings, up from -$13.5 million in the prior quarter.
- Across five years, Change in Receivables topped out at $434306.0 in Q1 2023 and bottomed at -$13.5 million in Q4 2025.
- A 5-year average of -$699321.9 and a median of $110025.0 in 2022 frame the typical range for Change in Receivables.
- Annual changes were most pronounced in 2022 — Change in Receivables surged 578.17% — and 2025, when it plunged 6444.99%.
- China Pharma Holdings' Change in Receivables stood at $107286.0 in 2022, then soared by 239.52% to $364258.0 in 2023, then sank by 41.54% to $212942.0 in 2024, then plunged by 6444.99% to -$13.5 million in 2025, then surged by 100.1% to $14019.0 in 2026.
- Business Quant data shows CPHI's Change in Receivables at $14019.0 in Q1 2026, -$13.5 million in Q4 2025, and $117491.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -78.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 106.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -621.82 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -38.20 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 126.30 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 81.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | China Pharma Holdings | 629,344.02 | 460,870.02 | 285,487.00 | 14,019.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14,019.00 |
| Mar 31, 2026 | 14,019.00 |
| Dec 31, 2025 | -13.51 Mn |
| Dec 31, 2025 | -13.51 Mn |
| Sep 30, 2025 | 117,491.00 |
| Sep 30, 2025 | 117,491.00 |
| Jun 30, 2025 | 20,566.00 |
| Jun 30, 2025 | 20,566.00 |
| Mar 31, 2025 | 164,670.00 |
| Mar 31, 2025 | 164,670.00 |
| Dec 31, 2024 | 212,942.00 |
| Dec 31, 2024 | 212,942.00 |
| Sep 30, 2024 | 167,299.00 |
| Sep 30, 2024 | 167,299.00 |
| Jun 30, 2024 | -62,163.00 |
| Jun 30, 2024 | -62,163.00 |
| Mar 31, 2024 | -120,370.00 |
| Mar 31, 2024 | -120,370.00 |
| Dec 31, 2023 | 364,258.00 |
| Dec 31, 2023 | 364,258.00 |